# INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

> **NCT04580485** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 54 (actual)

## Conditions studied

- Ovarian Cancer
- Bladder Cancer
- Non Small Cell Lung Cancer
- Squamous Cell Carcinoma of Head and Neck
- Triple Negative Breast Cancer
- Castration Resistant Prostate Cancer
- Colorectal Cancer
- Gastric/ Gastroesophageal Junction
- Hepatocellular Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Squamous Carcinoma of the Anal Canal

## Interventions

- **DRUG:** INCB106385
- **DRUG:** INCMGA00012

## Key facts

- **NCT ID:** NCT04580485
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-03
- **Primary completion:** 2024-01-22
- **Final completion:** 2024-01-22
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04580485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04580485, "INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04580485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*